Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd, together with its subsidiaries, engages in the pharmaceutical manufacturing and drug distribution busines...
REG - GSK PLC - Hansoh positive 2nd Phase III results for Riz-Rez
The traditional Chinese medicine concept continues to rise, WBDE hits the limit up, Honz, TMSP, Zhenbao Island, JI LIN AO DONG and others follow suit
TMSP's subsidiary received the drug re-registration approval notice
TMSP: Net profit of 10.2478 million yuan in the first half of 2025, turning from loss to profit
Some traditional Chinese medicine stocks saw their net profits double year-on-year in the first half of the year
Ophthalmology concept experiences a volatile rebound, TMSP hits the limit up